Mortality Risk of Patients With COVID-19 Prescribed SSRIs

JAMA Network Open


Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.


What The Study Did: Researchers analyzed electronic health records for about 83,000 patients diagnosed with COVID-19, including 3,401 patients prescribed selective serotonin reuptake inhibitors (SSRIs), to investigate whether SSRIs are associated with a lower risk of death among patients with COVID-19.

Authors: Marina Sirota, Ph.D., of the University of California, San Francisco, and David K. Stevenson, M.D., of the Stanford University School of Medicine in Stanford, California, are the corresponding authors.



Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.